Human Metabolome Technologies, Inc. (6090) AI Stock Analysis

Human Metabolome Technologies, Inc.

(TSE/TYO:6090)

Select Model

Rating:69Neutral

Price Target:JPY 648.00▲(11.34% Upside)

Action:reiterated

Date:08/10/26

The stock's overall score reflects a solid financial foundation with strong balance sheet and revenue growth, offset by declining profitability and bearish technical signals. The attractive valuation provides some support. While the company remains financially healthy, near-term price momentum is weak, leading to a neutral to slightly positive outlook.

Positive Factors

Conservative balance sheetVery low leverage and sizeable equity provide durable financial flexibility for a biotech services firm. This reduces refinancing and solvency risk, supports steady investment in instruments and R&D, and allows the company to pursue partnerships or weather industry cyclicality without forcing dilutive financing.

Negative Factors

Uneven cash conversionVolatile conversion of earnings into operating cash suggests working-capital swings or timing differences that can strain liquidity during growth phases. Persistent uneven conversion complicates budgeting, increases reliance on short-term funding when scaling, and weakens predictability of cash returns to shareholders.

Human Metabolome Technologies, Inc. (6090) vs. iShares MSCI Japan ETF (EWJ)

Market Cap: JPY 3.15B
Dividend Yield: 3.09%
Average Volume (3M): 4,116
Price to Earnings (P/E): 16.1
Beta (1Y): 0.27
Revenue Growth: -2.27%
EPS Growth: -17.23%
Country: Japan
Employees: 65
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

Human Metabolome Technologies, Inc. Business Overview & Revenue Model

Company Description

Human Metabolome Technologies, Inc. is a biotechnology company based in Tsuruoka, Japan, established in 2003. It focuses on developing and providing metabolomics technologies and solutions for a range of applications, including drug discovery, diseas...

How the Company Makes Money

null

Human Metabolome Technologies, Inc. Financial Statement Overview

Summary

Revenue growth remains positive (9.7% in latest year), but profitability margins have declined, reducing net income. Balance sheet is strong with minimal debt (debt-to-equity 0.057) and high equity. Cash flow generation is solid though somewhat volatile. Overall financial performance is stable but faces challenges in margins.

Income Statement

62Positive

Balance Sheet

85Very Positive

Cash Flow

70Positive

Financial statement breakdown
Breakdown	TTM	Jun 2025	Jun 2024	Jun 2023	Jun 2022	Jun 2021
Income Statement
Total Revenue	1.42B	1.42B	1.46B	1.35B	1.30B	1.22B
Gross Profit	868.52M	868.52M	922.00M	869.33M	859.75M	840.00M
EBITDA	340.50M	321.26M	353.00M	350.31M	319.65M	329.02M
Net Income	200.36M	200.36M	256.00M	243.25M	285.76M	267.79M
Balance Sheet
Total Assets	2.28B	2.28B	2.37B	2.60B	2.29B	2.07B
Cash, Cash Equivalents and Short-Term Investments	1.44B	1.44B	1.59B	1.79B	1.66B	1.50B
Total Debt	103.88M	103.00M	110.47M	226.30M	226.52M	233.19M
Total Liabilities	451.39M	451.39M	466.13M	656.84M	518.91M	583.39M
Stockholders Equity	1.83B	1.83B	1.91B	1.95B	1.77B	1.49B
Cash Flow
Free Cash Flow	0	148.52M	225.00M	202.70M	168.11M	177.92M
Operating Cash Flow	0	208.58M	373.00M	236.79M	284.96M	324.03M
Investing Cash Flow	0	-83.37M	-197.00M	-32.44M	-116.75M	-152.31M
Financing Cash Flow	0	-281.76M	-369.00M	-73.15M	-13.75M	80.49M

Human Metabolome Technologies, Inc. Technical Analysis

Technical Analysis SentimentNegative

Last Price582.00

Price Trends

50DMA607.36Negative

100DMA604.81Negative

200DMA637.95Negative

Market Momentum

MACD-5.86Positive

RSI33.72Neutral

STOCH25.00Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:6090, the sentiment is Negative. The current price of 582.00 is below the 20-day moving average (MA) of 596.30, below the 50-day MA of 607.36, and below the 200-day MA of 637.95, indicating a bearish trend. The MACD of -5.86 indicates Positive momentum. The RSI at 33.72 is Neutral, neither overbought nor oversold. The STOCH value of 25.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:6090.

Human Metabolome Technologies, Inc. Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

JP:6090 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
JP:4694	72Outperform	JPY 143.41B	18.09	6.22%	3.37%	3.88%	26.78%
JP:3386	69Neutral	JPY 7.16B	19.16	―	4.07%	9.39%	44.42%
JP:6090	69Neutral	JPY 3.50B	16.08	―	3.09%	-2.27%	-17.23%
JP:2395	63Neutral	JPY 62.70B	11.67	―	3.32%	1.72%	6.07%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
JP:4882	42Neutral	JPY 2.62B	-2.83	―	―	19.70%	17.73%

* Healthcare Sector Average

Performance Comparison

JP:6090 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
JP:6090	Human Metabolome Technologies, Inc.	582.00	-90.32	-13.43%
JP:4694	BML	3780.00	276.68	7.90%
JP:2395	Shin Nippon Biomedical Laboratories, Ltd.	1506.00	78.94	5.53%
JP:3386	Cosmo Bio Co., Ltd.	1229.00	162.47	15.23%
JP:4882	Perseus Proteomics, Inc.	136.00	-160.00	-54.05%

Human Metabolome Technologies, Inc. Corporate Events

Human Metabolome Technologies Posts Lower Earnings but Maintains Strong Capital Base

Aug 7, 2026

Human Metabolome Technologies, Inc., a metabolomics-focused analytical services provider listed on the Tokyo Stock Exchange Standard market, reported slight declines in revenue and profit for the fiscal year ended June 30, 2026. Despite softer result...

Human Metabolome Technologies Posts Profit Decline but Maintains Strong Capital Base

May 13, 2026

Human Metabolome Technologies, Inc., listed on the Tokyo Standard market, operates in the life-science analytics and metabolomics sector, supplying analytical technologies and services to pharmaceutical, biotech, and research institutions. Its offeri...

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Aug 10, 2026

Human Metabolome Technologies, Inc. AI Stock Analysis